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The radio-iodinated noradrenaline analogue meta-iodobenzylguanidine (MIBG) can be used for scintigraphy and radiation therapy of
neuroendocrine (NE). The aim of the present study was to study the importance of vesicular monoamine transporters (VMATs) for
the uptake of
123I-MIBG in NE tumours. In nude mice, bearing the human transplantable midgut carcinoid GOT1, all organs and
xenografted tumours accumulated
123I after i.v. injection of
123I-MIBG. A high concentration of
123I was maintained in GOT1 tumours
and adrenals, which expressed VMATs, but rapidly decreased in all other tissues. In the VMAT-expressing NE tumour cell lines GOT1
and BON and in VMAT-expressing primary NE tumour cell cultures (carcinoids, n¼4 and pheochromocytomas, n¼4), reserpine
significantly reduced the uptake of
123I-MIBG. The membrane pump inhibitor clomipramine had no effect on the uptake of
123I-MIBG
in GOT1 and BON cells, but inhibited the uptake in one out of four primary carcinoid cell cultures and three out of four primary
pheochromocytoma cell cultures. In conclusion, VMATs and secretory granules are of importance for the uptake and retention of
123I-MIBG in NE tumours. Information about the type and degree of expression of VMATs in NE tumours may be helpful in future to
select patients suitable for radiation therapy with radio-iodinated MIBG.
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Amine-producing neurons and neuroendocrine (NE) cells have the
capacity to synthesise, store and release amines. Amines are
synthesised in the cytoplasm and transported into storage vesicles
by specific membrane-bound transporters, that is, vesicular
monoamine transporters (VMATs). Once released from the cell,
amines can be subject to reuptake by another set of transporters
localised to the plasma membrane (Rothman and Orci, 1992;
Calakos and Scheller, 1994). Two subtypes of vesicular monoamine
transporters, VMAT1 and 2, have been characterised with
structural similarities, but with differences in substrate specificity
and tissue distribution (Erickson et al, 1992; Liu et al, 1992;
Erickson and Eiden, 1993). In a recent study, we demonstrated the
differential expression of VMAT1 and 2 in gut NE tumours,
reflecting specific amine production and different cellular origin of
these tumours. Serotonin-producing enterochromaffin (EC) cell
carcinoids (midgut carcinoids) expressed VMAT1 and 2, while
histamine-producing enterochromaffin-like (ECL) cell carcinoids
(foregut carcinoids) expressed VMAT2 almost exclusively. Rectal
carcinoids and pancreatic endocrine tumours with predominant
peptide production expressed VMATs only rarely (Jakobsen et al,
2001).
Neuroendocrine tumours can be visualised by scintigraphy after
injection of the radio-iodinated noradrenaline analogue meta-
iodobenzylguanidine (MIBG), which is a substrate for the amine
transporters of chromaffin granules (Henry et al, 1994). In clinical
studies, the uptake of radiolabelled MIBG was high in pheochro-
mocytomas (derived from the adrenal medulla) in comparison
with midgut carcinoid tumours (Kimmig, 1994). Pheochromocy-
tomas express high levels of both VMAT1 and 2, while serotonin-
producing midgut carcinoids express mainly VMAT1 (Jakobsen
et al, 2001). The importance of VMAT expression, functional
status or the presence of isoforms of VMAT in NE tumours has not
been established.
The aim of the present study was therefore to study the uptake
of
123I-MIBG in NE tumours in relation to the expression of VMAT
isoforms.
MATERIALS AND METHODS
Animal model
Male BALB/cABom-nu mice, 3–4 weeks of age (Bomholtgaard,
Denmark), were used for transplantation. Tumour tissue was
harvested from nude mice, carrying xenografts of the human
transplantable midgut carcinoid tumour GOT1, and propagated to
new animals every 3 months (Ko ¨lby et al, 2001). Tumours were
minced and small pieces (2 2 1mm each) were transplanted to
the subcutis in the back of the neck. After 3–4 months, the
tumours measuring 10mm in diameter were used for MIBG uptake Revised 16 June 2003; accepted 24 July 2003
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Committee for Animal Experiments, Go ¨teborg University.
Biodistribution and scintigraphy of
123I-MIBG in nude
mice
The biodistribution of
123I-MIBG (Mallinckrodt, Petten, Holland)
was studied in eight nude mice carrying GOT1 tumours at 4h
(n¼2), 24h (n¼3) and 48h (n¼3) after i.v. injection of 10–
12MBq into the tail vein. Prior to and after the administration of
the
123I-MIBG, the
123I activity in the syringes was measured with a
well-type ionisation chamber (CRC-120, Capintec, USA). Tumours
and tissue samples from the salivary gland, lung, kidney, heart,
spleen, adrenal, small intestine, muscle and blood were collected
and weighed. The
123I activity was measured in a Wallac 1480
gamma counter (WIZARD3, Wallac Oy, Finland) and the data were
corrected for background and physical decay. The calibration
factor between the sensitivity of the ionisation chamber and the
gamma counter was determined. The
123I activity concentration of
the radionuclide was expressed as the fraction of injected activity
per unit mass of the tissue (%IA/g), and the tumour-to-blood
activity concentration ratio, T/B, was determined (Forssell-
Aronsson et al, 1995). Before killing, whole-body scintigraphies
were performed with a gamma camera (General Electric AC/T, UK)
equipped with a pinhole collimator.
123I-MIBG binding in cell cultures
The binding of
123I-MIBG was studied in two human NE tumour
cell lines (GOT1, derived from a midgut carcinoid; BON, derived
from a pancreatic carcinoid) and one non-NE tumour cell line
(Colo205, derived from a colon carcinoma) (Semple et al, 1978;
Evers et al, 1991; Ko ¨lby et al, 2001). GOT1 cells were grown in
RPMI 1640 supplemented with 4% foetal calf serum (FCS). BON
cells were grown in DMEMþF-12 with 10% FCS. Colo205 cells
were grown in Iscove’s medium supplemented with 10% FCS. The
binding of
123I-MIBG was also studied in eight primary tumour cell
cultures established from four patients with metastatic ileal
carcinoid tumours (cases 1–4) and four with adrenal pheochro-
mocytomas (cases 5–8). Tumour tissues were obtained from
primary tumours, or liver metastases, from patients undergoing
surgery. The preparation and characterisation of tumour cell
cultures have been described previously (Westberg et al, 1997).
Tumour cells were seeded onto collagen-coated tissue-culture
plates (Nunc, IL, USA) at a density of 10
5–10
6 cells per well and
incubated in RPMI 1640 medium (Northumbria Biologicals,
Cramlington, UK) supplemented with 4% FCS. The experiments
were performed on tumour cells after 2 weeks in primary culture.
Cultures from all tumours contained a majority of tumour cells
(490%) with a minor population of fibroblasts.
The tumour cells were incubated at 371C for 4h with 100ml
RPMI 1640 medium containing approximately 500Bq
123I-MIBG
(corresponding to 10nM of MIBG). For blockade of the MIBG
binding at the granule membrane or at the plasma membrane, the
medium was supplemented with reserpine (1mM) or clomipramine
(1mM), 30min before the addition of MIBG, respectively. After
incubation for 4h with
123I-MIBG, the medium was removed and
the cells were washed rapidly three times with 1ml Ca- and Mg-
free DPBS. The cells were detached from the wells by gentle
flushing with 1ml DBPS containing 5mgml
 1 H-33342 (bis-
Benzimide, Hoechst, H-33342), and transferred to a plastic tube.
The amount of cell-bound
123I was determined by radioactivity
measurements of the tube contents using the gamma counter.
Correction was made for background and radioactive decay. For
DNA quantification, the cells were transferred to a 96-well plate for
the measurement of fluorescence intensity, using excitation and
emission wavelengths of 355 and 460nm, respectively (Spectra
Max Gemini, Molecular Devices, USA). A standard curve was made
by measurements of serial dilutions of DNA (salmon testes DNA,
cat. no. D7656, Sigma Chemical Co, St Louis, MO, USA) in DPBS
with 5mgml
 1 H-33342. The binding of
123I-MIBG to the cell lines
was correlated to the amount of DNA in each well. The binding of
123I-MIBG was expressed as the fraction of activity administered
per mg DNA (%AAmg
 1). For the primary cell cultures, the cellular
binding was expressed as the fraction of activity administered per
well.
Immunocytochemistry
Tissues were fixed in 4% neutral buffered formalin in PBS at pH
7.4. for 4–48h, dehydrated and embedded in paraffin wax. The
sections were incubated overnight with primary antisera (Table 1).
The bound antibodies were visualised by an indirect immunoper-
oxidase technique using tyramide signal amplification (TSA-
Indirect, NEN Life Science Products, MA, USA). Diaminobenzidine
(DAB) was used as a chromogen. The control sections were
incubated identically, except for the primary antibodies, which
were replaced by normal mouse IgG, normal rabbit or goat serum.
Cells, grown on collagen-coated slides (Chamber Slide
s; Nunc
Inc.), were fixed in 4% buffered formalin in PBS at pH 7.4 for 4h,
and incubated for indirect immunofluoresence. Preincubation with
5% nonfat dry milk was followed by overnight incubation with
primary antisera (Table 1). The bound antibodies were visualised
using biotin-labelled secondary antibodies and streptavidin–FITC.
Control cultures were incubated identically, except for the primary
antibodies, which were replaced by normal mouse IgG or normal
rabbit or goat serum. Cultures were examined with a Nikon Eclipse
E800 microscope equipped with epi-illumination.
Western blotting
Tumour biopsies and cultured cells were homogenised in 10mM
potassium-phosphate buffer (pH 6.8). containing 1mM EDTA,
10mM CHAPS, 1mgml
 1 aprotinin, 10mgml
 1 leupeptin,
10mgml
 1 pepstatin and 1mgml
 1 Pefablock
s (all chemicals from
Roche Diagnostics GmbH, Mannheim, Germany). Aliquots of
proteins (20mg) were separated by electrophoresis in precast
polyacrylamide gels (10% NuPAGE Bis-Tris-gels; Invitrogen,
Table 1 Primary antibodies used for immunocytochemistry and Western blotting
Antibody
Dilution,
immuno-
fluorescence
Dilution,
immuno-
peroxidase
Dilution,
Western
blotting Clone Cat. no Company
VMAT1 (goat) 1:100 1:1000 1:2000 sc-7718 Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA
VMAT1 (rabbit) 1:100 1:10000 — Gift from Jeffrey D Erickson, NIH, MD, USA
VMAT2 (rabbit) 1:100 1:10000 — Jeffrey D Ericksson
VMAT2 (rabbit) 1:100 1:1000 1:2000 AB1767 Chemicon, Temecula, CA, USA
CgA (mouse) 1:500 1:1000 — LK2H10 1199021 Boehringer Mannheim, Mannheim, Germany
SV2 (mouse) 1:20 — — Development Studies, Hybridoma Bank
—¼not tested.
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Proteins were transferred on to polyvinyldifluoride (PVDF)
membranes using a NOVEX blotting system. The membranes
were incubated with anti-VMAT1 or anti-VMAT2 antisera
followed by alkaline phosphate-conjugated goat anti-rabbit anti-
bodies, and chemoluminescence detection (Table 1). Molecular
weight markers (Sea-Blue, Invitrogen) were used to calculate the
apparent size of immunoreactive proteins.
Statistical analysis
For statistical analysis, the Student’s t-test was used. P-values
o0.05 were considered to be significant.
RESULTS
Biodistribution of
123I-MIBG in nude mice with GOT1
xenografts
The activity concentration of
123I in tumour tissue was 0.
9370.06%IAg
 1 (mean7s.e.m.) IAg
 1 (n¼2) at 4h,
1.170.13%IAg
 1 (n¼3) at 24h and 0.5470.08%IAg
 1 (n¼3)
at 48h after injection. The corresponding T/B values were 1272,
2875 and 83713. At 4h after injection, the concentration
in the adrenal was 3.4%IAg
 1, in the salivary gland 6.3%IAg
 1
and in the lung, kidney, heart, liver, spleen and muscle it
ranged between 0.32 and 1.7%IAg
 1. In the tumour and the
adrenal, the concentration remained stable over the 48h period,
while the concentration declined rapidly in all the other organs
(Figure 1).
Scintigraphy at 4h showed a widespread distribution of the
radionuclide and the tumour was therefore not scintigraphically
detectable. At 24h, the tumour was clearly visible and the
radionuclide could also be detected in the salivary glands and
urinary bladder. At 48h, the tumour was no longer scintigraphi-
cally detectable (Figure 2).
123I-MIBG binding to cultured tumour cells; effects of
reserpine and clomipramine
All tumour cell lines investigated accumulated
123I-MIBG. Binding
to GOT1, BON and Colo205 cells was 4.0, 1.1 and 1.1%AAmg
 1
DNA, respectively. Reserpine significantly inhibited the binding in
the NE cell lines; GOT1: 43% reduction (Po0.02) and BON: 31%
reduction (Po0.05). In the non-NE tumour cell line Colo205,
reserpine had no effect on the binding of
123I-MIBG. Clomipramine
had no significant effect on the binding of
123I-MIBG in any of the
human cell lines investigated (Figure 3).
In the primary cell cultures derived from midgut carcinoid
tumours, the binding of
123I-MIBG ranged between 1.2 and 21%
per well. Reserpine strongly reduced the
123I-MIBG binding in the
ileal carcinoids; case no. 1: 79% reduction (Po0.001); case no. 2:
66% reduction, (Po0.001); case no. 3: 68% reduction (Po0.001);
and case no. 4: 28% reduction (Po0.001) (Figure 4a).
Clomipramine inhibited the binding of
123I-MIBG in one ileal
carcinoid; case no. 2: 25% reduction (Po0.01). In contrast,
clomipramine had no effect on
123I-MIBG binding in the other ileal
carcinoids (case nos. 1, 3 and 4) (Figure 4A).
In primary cell cultures derived from pheochromocytomas, the
binding of
123I-MIBG ranged between 0.94 and 15% per well.
Reserpine strongly reduced the
123I-MIBG binding in all pheo-
chromocytomas investigated; case no. 5: 86% reduction
(Po0.001); case no. 6: 95% reduction (Po0.001); case no. 7:
32% reduction (Po0.001); and case no. 8: 47% reduction
(Po0.001).
Clomipramine also reduced the binding in three of four
pheochromocytomas; case no. 5: 48% reduction (Po0.001); case
no. 6: 99% reduction (Po0.001); and case no. 8: 79% reduction
(Po0.001). In contrast, clomipramine had no effect on
123I-MIBG
binding in case no. 7 (Figure 4B).
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Figure 1 Biodistribution of
123I-MIBG in nude mice. Results are given as
percent of injected activity per gram of tissue (%IAg
 1) (mean7s.e.m.). In
the tumour and the adrenals, the concentration remained relatively stable
over the 48h period, while the concentration declined rapidly in all other
organs.
Figure 2
123I-MIBG-scintigraphy of nude mice with the GOT1 tumour growing in the back of the neck. At 4h (left), there was a widespread distribution
of
123I-MIBG and the tumour was not detectable. After 24h (right), the uptake in the tumour (T) remained high and it was now clearly visible. Both at 4 and
24h, the salivary glands (S) and urinary bladder (B) were visible.
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Immunocytochemical analysis showed that xenografted GOT1
tumours and the adrenal medulla of host animals were strongly
positive for VMAT1 and 2. The VMAT1 and 2 immunoreactive
material was located in the secretory granules in the cytoplasm of
tumour cells and adrenal chromaffin cells. All the other organs
investigated were negative for VMAT1 and 2. The NE tumour cell
lines GOT1 and BON were both positive for VMAT1 and 2, SV2
and CgA immunocytochemically. The immunoreactive material
was located in secretory granules in the cytoplasm of the tumour
cells. Colo205 tumour cells were negative for all these markers
(Table 2 and Figure 5). Immunofluorescence analysis of primary
cell cultures demonstrated VMAT1 in four of four carcinoids and
three of four pheochromocytomas, whereas VMAT2 was present in
three of four carcinoids and four of four pheochromocytomas.
Immunoperoxidase staining of tumour biopsies demonstrated the
expression of VMAT1 in seven of eight tumours and VMAT2 in
eight of eight tumours (Table 3).
Western blotting of tumour biopsies confirmed the expression
pattern obtained by immunocytochemical analysis (Table 3).
VMAT1 migrated as one broad band with a molecular weight of
65–95kDa, while VMAT2 appeared in two bands: a major band at
65–90kDa and a minor band at 40–50kDa.
DISCUSSION
Radio-iodinated MIBG can be used for scintigraphic visualisation
of NE tumours by scintigraphy and for targeted radiation therapy.
Pheochromocytomas and neuroblastomas rapidly accumulate
MIBG and are therefore efficiently visualised by MIBG scintigra-
phy, while only about one-third of carcinoid tumours can be
visualised by this technique (Kimmig, 1994). The reason why
certain carcinoid tumours cannot be visualised has not been
explained, and the precise mechanism behind MIBG uptake and
retention in NE tumours is unclear. It has been shown that MIBG is
a substrate for VMATs, located on the membrane of secretory
vesicles of NE cells (Henry et al, 1994; Erickson et al, 1996). It is
therefore likely that after passing the plasma membrane, MIBG is
transported into secretory granules by VMATs. In this study, we
have demonstrated that
123I was widely distributed to several
organs of nude mice with GOT1 xenografts 4h after the
administration of
123I-MIBG. However, the long-term retention
of radioactivity was only observed in tissues expressing high levels
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Figure 3 Effect of reserpine and clomipramine on
123I-MIBG binding to
cultured cell lines. Results are given as the percentage (mean7s.e.m.) of
administered activity per microgram DNA (%AAmg
 1). The uptake in
GOT1, BON and Colo205 cells was 4.0, 1.1 and 1.1%AAmg
 1 DNA,
respectively. The VMAT antagonist reserpine significantly inhibited the
binding in the NE tumour cell lines GOT1 and BON, whereas it had no
effect on the non-NE tumour cell line Colo205. Clomipramine had no
significant effect on the binding of
123I-MIBG in any of the cell lines
investigated.
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Figure 4 (A) Effect of reserpine and clomipramine on
123I-MIBG binding
to primary carcinoid tumour cell cultures. Reserpine strongly reduced the
123I-MIBG uptake in all cases. Clomipramine had no effect on
123I-MIBG
uptake in three out of four ileal carcinoids (case nos. 1, 3 and 4). In contrast,
clomipramine had an inhibitory effect on
123I-MIBG uptake in one ileal
carcinoid (case no. 2). Values are given as mean7s.e.m. (B) Effect of
reserpine and clomipramine on
123I-MIBG binding to primary cell cultures
of pheochromocytomas. Reserpine strongly reduced the
123I-MIBG binding
to all the pheochromocytomas investigated. Clomipramine also reduced
the binding to three out of four pheochromocytomas (case nos. 5, 6 and 8),
whereas it had no effect on the binding in case no. 7. Values are given as
mean7s.e.m.
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corroborated by the results from the NE and non-NE tumour
cell lines. All the cell lines showed binding of
123I-MIBG, but only
NE cell lines expressing VMATs had their binding reduced by
the VMAT antagonist reserpine. These results indicate that the
secretory granules containing VMATs are of importance for
the uptake and retention of MIBG in tumour tissues.
The specific role of plasma membrane transporters for the
binding of MIBG in tumour cells still remains unclear. Previous
studies on midgut carcinoid tumours in primary culture have
indicated the presence of transporters at the plasma membrane in
these tumours (Wa ¨ngberg et al, 1990). However, inhibition of the
membrane pump by clomipramine had no effect on MIBG uptake
in any of the carcinoid tumour cell lines investigated. The results
from nude mice with widespread distribution of MIBG in several
organs, together with the negative results with clomipramine in the
cell line studies, indicate alternative transport mechanisms for
MIBG to pass the plasma membrane of carcinoid tumour cells.
This was corroborated by the results from primary carcinoid cell
cultures, which in three out of four cases, did not respond to
clomipramine. On the other hand, clomipramine markedly
reduced the uptake of MIBG in almost all catecholamine-handling
primary pheochromocytoma cell cultures. This indicates that
pheochromocytomas predominantly use the noradrenaline trans-
porter for the uptake of MIBG across the plasma membrane.
Immunocytochemical analysis of tumour biopsies revealed that
all tumours examined expressed VMAT1 and/or VMAT2. The
quantitative expression of each VMAT vs MIBG uptake and
retention was not determined in the present experiments. The
expression of VMAT was maintained in the cell culture. The
specific uptake of MIBG in cultured tumour cells was demon-
strated in VMAT-expressing tumours (both carcinoids and
pheochromocytomas) and this uptake was antagonised reserpine.
In primary cell culture, blockade of the noradrenergic membrane
pump by clomipramine was effective only in one out of four
carcinoids and in three out of four pheochromocytomas. These
results confirm the hypothesis that VMATs are of importance for
the uptake of MIBG in amine-handling NE tumour cells.
In conclusion, this study shows that VMATs are of primary
importance for uptake and retention of the catecholamine
analogue MIBG in NE tumour cells. The storage of MIBG in
secretory granules was markedly reduced by the VMAT antagonist
reserpine. A common mechanism behind MIBG transport across
the plasma membrane could not be shown in these experiments.
Pheochromocytoma cells utilised the noradrenaline transporter,
antagonized by clomipramine. On the other hand, uptake of MIBG
into carcinoid cells was antagonised by reserpine, but only
occasionally by clomipramine. A better understanding of the
mechanisms behind MIBG uptake in NE tumours will be helpful to
select patients suitable for therapy with radio-iodinated MIBG.
Table 2 Expression of VMAT1 and 2 and secretory granule markers in
cell lines analysed by immunocytochemistry
Immunocytochemistry
VMAT1 VMAT2 SV2 CgA
GOT1 + + + +
BON + + + +
Colo205       
+¼present;  ¼absent.
Figure 5 Immunocytochemical examination of the NE tumour cell lines
GOT1 and BON and the non-NE tumour cell line Colo205. GOT1 and
BON cells were both positive for VMAT1 and 2, SV2 and CgA. Colo205
cells were negative for all these markers. The scale bar represents 10mm.
Table 3 Expression of VMAT1 and 2 in primary cell cultures (MC¼midgut carcinoid, PC¼pheochromocytoma)
Immunocytochemistry
Biopsy  /+ +++ scale
a Cell culture  /+ scale Western blot  /+ scale
Primary cell culture
no./tumour type
VMAT1 VMAT2 VMAT1 VMAT2 VMAT1 VMAT2
1 MC +++ ++ +   +  
2 MC +++ +++ + + + +
3 MC +++ +++ + + + +
4 MC +++ +++ + + + +
5 PC +++ +++ + + + +
6 PC +++ +++ + + + +
7P C   +++   +   +
8 PC +++ +++ + + + +
a+¼1–25% of tumour cells positive; ++¼25–75% of tumour cells positive; +++¼75–100% of tumour cells positive.
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to enhance the therapeutic effects.
ACKNOWLEDGEMENTS
We thank Siv Tuneberg, Ann Wikstro ¨m, Annki Illerskog, Ellinor
Andersson, Gu ¨lay Altiparmak and Malin Bengtsson for expert
technical assistance. This study was supported by The Swedish
MRC (5220), The Swedish Cancer Society (3427 and 3911), the IB &
A Lundberg Research Foundation, the Assar Gabrielsson
Foundation, the Swedish Society of Medicine, the Swedish
Society for Medical Research, the Go ¨teborg Medical Society,
the King Gustav V Jubilee Clinic Cancer Fund, Go ¨teborg, the
Sahlgrenska University Hospital Research Funds, the Gunvor &
Josef Ane ´r Foundation, the Axel Linder Foundation, the
Gunnar, Arvid and Elisabeth Nilsson Foundation, the B Uhlander
Fund, the C Landgren Memorial Fund, the Serena Ehrenstro ¨m
Foundation and the Wilhelm and Martina Lundgren Research
Fund.
REFERENCES
Calakos N, Scheller RH (1994) Vesicle-associated membrane protein and
synaptophysin are associated on the synaptic vesicle. J Biol Chem 269:
24534–24537
Erickson JD, Eiden LE (1993) Functional identification and molecular
cloning of a human brain vesicle monoamine transporter. J Neurochem
61: 2314–2317
Erickson JD, Eiden LE, Hoffman BJ (1992) Expression cloning of a
reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci
USA 89: 10993–10997
Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996) Distinct
pharmacological properties and distribution in neurons and endocrine
cells of two isoforms of the human vesicular monoamine transporter.
Proc Natl Acad Sci USA 93: 5166–5171
Evers BM, Townsend Jr CM, Upp JR, Allen E, Hurlbut SC,
Kim SW, Rajaraman S, Singh P, Reubi JC, Thompson JC (1991)
Establishment and characterization of a human carcinoid in nude mice
and effect of various agents on tumor growth. Gastroenterology 101:
303–311
Forssell-Aronsson E, Fja ¨lling M, Nilsson O, Tisell LE, Wa ¨ngberg B, Ahlman
H (1995) Indium-111 activity concentration in tissue samples after
intravenous injection of indium-111-DTPA-D-Phe-1-octreotide. J Nucl
Med 36: 7–12
Henry JP, Gasnier B, Desnos C, Scherman D, Krejci E, Massoulie J (1994)
The catecholamine transporter of adrenal medulla chromaffin granules.
Ann NY Acad Sci 733: 185–192
Jakobsen AM, Andersson P, Saglik G, Andersson E, Ko ¨lby L, JD, E, Forssell-
Aronsson E, Wa ¨ngberg B, Ahlman H, Nilsson O (2001) Expression of
vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal
endocrine tumors. J Pathol 195: 463–472
Kimmig BN (1994) Radiotherapy for gastroenteropancreatic neuroendo-
crine tumors. Ann NY Acad Sci 733: 488–495
Ko ¨lby L, Bernhardt P, Ahlman H, Wa ¨ngberg B, Johanson V, Wigander A,
Forssell-Aronsson E, Karlsson S, Ahre ´n B, Stenman G, Nilsson O (2001)
A transplantable human carcinoid as model for somatostatin receptor-
mediated and amine transporter-mediated radionuclide uptake. Am J
Pathol 158: 745–755
Liu Y, Peter D, Roghani A, Schuldiner S, Prive GG, Eisenberg D, Brecha N,
Edwards RH (1992) A cDNA that suppresses MPP+ toxicity encodes a
vesicular amine transporter. Cell 70: 539–551
Rothman JE, Orci L (1992) Molecular dissection of the secretory pathway.
Nature 355: 409–415
Semple TU, Quinn LA, Woods LK, Moore GE (1978) Tumor and lymphoid
cell lines from a patient with carcinoma of the colon for a cytotoxicity
model. Cancer Res 38: 1345–1355
Westberg G, Ahlman H, Nilsson O, Illerskog A, Wa ¨ngberg B (1997)
Secretory patterns of tryptophan metabolites in midgut carcinoid tumor
cells. Neurochem Res 22: 977–983
Wa ¨ngberg B, Ahlman H, Nilsson O, K, H, Denney RM, Dahlstro ¨m A (1990)
Amine handling properties of human carcinoid tumour cells in tissue
culture. Neurochem Int 17: 331–341
MIBG uptake in neuroendocrine tumours
LK o ¨lby et al
1388
British Journal of Cancer (2003) 89(7), 1383–1388 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s